Evidence map›Paper›PMID 39971829›Full record

ArticleDigestive diseases and sciences2025

PPIs Have It: Does Tegoprazan Affect Gastric Emptying and Produce Dyspeptic Symptoms?

José María Remes-Troche

Abstract readEditorial
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

José María Remes-TrocheLaboratorio de Fisiología Digestiva y Motilidad Gastrointestinal, Instituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, Iturbide s/n entre Carmen Serdán y 20 de Noviembre, col. Centro, Veracruz, Veracruz, Mexico. joremes@uv.mx.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The potassium-competitive acid blockers (P-CABs) are a novel class of potent antisecretory drugs that unlike the proton pump inhibitors (PPIs) are not dependent on activated proton pumps, acting near maximally from the first dose, a pharmacokinetic advantage over PPIs. Tegoprazan, a novel P-CAB, offers potent and rapid acid suppression without delaying gastric emptying, distinguishing it from PPIs. This commentary contextualizes these results within the broader landscape of functional dyspepsia management, highlighting the potential benefits of tegoprazan in patients requiring antisecretory therapy, emphasizing the need for further research into its long-term impacts on motility, gut microbiota composition, and symptomatology. This analysis underscores how P-CABs may redefine antisecretory therapies.

Indexed as

DyspepsiaGastric EmptyingProton Pump InhibitorsHumansPyrrolesSulfonamides1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineProton Pump InhibitorsPyrrolesSulfonamidesDyspepsiaGastric emptyingPotassium-competitive acid blockersProton pump inhibitorsSmall intestinal bacterial overgrowth

Identifiers

PMID39971829

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.